CAR T-cell therapies have exhibited strong and durable responses in several hematological malignancies thus far. Now bb2121, an anti-BCMA CAR T-cell product, is demonstrating impressive responses in relapsed/refractory multiple myeloma (MM). In this interview, Yi Lin, MD, PhD, of the Mayo Clinic, Rochester, MN, discusses the latest results of the ongoing CRB-401 trial (NCT02658929) of bb2121 for MM. Dr Lin covers the promising progress, response rates, response durability, MRD status and safety data from the trial so far. She also highlights the long-term follow-up and FDA breakthrough treatment designation of the product. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Anti-BCMA CAR T-cells for MM: durable clinical responses with bb2121
